Osteoporosis Drugs Market Size and Forecast 2024-2033| Pfizer Inc., F. Hoffmann La Roche Ltd., Merck & Co Inc., Novartis AG, Bristol Myers Squibb Company,

Making sure it's crystal clear

The Osteoporosis Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Osteoporosis Drugs Market:

https://www.thebusinessresearchcompany.com/report/osteoporosis-drugs-global-market-report

According to The Business Research Company’s Osteoporosis Drugs Global Market Report 2024, The osteoporosis drugs market size has grown steadily in recent years. It will grow from $12 billion in 2023 to $12.48 billion in 2024 at a compound annual growth rate (CAGR) of 4.0%. The growth in the historic period can be attributed to aging population, increased awareness and diagnosis, lifestyle factors, government initiatives and healthcare policies.

The osteoporosis drugs market size is expected to see steady growth in the next few years. It will grow to $14.2 billion in 2028 at a compound annual growth rate (CAGR) of 3.3%. The growth in the forecast period can be attributed to continued aging population trends, advancements in treatment options, increased focus on men’s bone health, patient education and empowerment, global health policies and insurance coverage. Major trends in the forecast period include personalized medicine approaches, exploration of combination therapies, focus on fracture prevention strategies, R&D investment in novel drug targets, collaborations for drug development.

A surge in the prevalence of osteoporosis is expected to propel the growth of the osteoporosis drug market. Osteoporosis is a bone disease that occurs when bone mineral density and mass bone decline or when bone quality or structure changes. People who have a low calcium intake are more likely to develop osteoporosis. These osteoporosis drugs increase bone mineral density and help to prevent fractures. For instance, In May 2022, according to statistics published by Amgen, a US-based biotechnology company, states that every year, osteoporosis causes roughly 1.5 million fractures in the United States, resulting in $19 billion in associated costs. Furthermore, the annual number of fractures caused by osteoporosis is expected to rise by 68% from 2018 to 2040, i.e., from 1.9 million to 3.2 million. Therefore, the surging prevalence of osteoporosis is driving the growth of the osteoporosis drugs market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=9102&type=smp

The osteoporosis drugs market covered in this report is segmented –

1) By Type: Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), RANK Ligand Inhibitors

2) By Administration: Oral, Injectable

3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Sales

4) By Application: Primary Osteoporosis, Secondary Osteoporosis

Major companies operating in the osteoporosis drug market are focusing on strategic partnerships to provide reliable services to customers. A strategic partnership is an arrangement between two or more companies or organizations that helps each other or works together to achieve their respective goals. For instance, in December 2022, Chugai Pharmaceutical Co. Ltd., a Japan-based drug manufacturer operating pharmaceutical company, partnered with Towa Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company manufacturer of generic drugs dedicated to R&D, manufacturing, and marketing, to launch Edirol Tablet for an osteoporosis treatment. Chugai manufactures Edirol tablets and supplies them to Towa. Edirol is an active vitamin D3 derivative created by Chugai that can improve calcium and bone metabolism. This launch contributes to the osteoporosis drug market by providing a new treatment option for this condition.

The osteoporosis drugs market report table of contents includes:

1. Executive Summary

2. Osteoporosis Drugs Market Characteristics

3. Osteoporosis Drugs Market Trends And Strategies

4. Osteoporosis Drugs Market – Macro Economic Scenario

5. Global Osteoporosis Drugs Market Size and Growth

26. South America Osteoporosis Drugs Market

27. Brazil Osteoporosis Drugs Market

28. Middle East Osteoporosis Drugs Market

29. Africa Osteoporosis Drugs Market

30. Osteoporosis Drugs Market Competitive Landscape And Company Profiles

Top Major Players: